AMG 172
/ Amgen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 28, 2019
First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.
(PubMed, Cancer Chemother Pharmacol)
- "AMG 172 exhibited a favorable pharmacokinetic profile in patients with relapsed/refractory ccRCC and showed evidence suggestive of limited antitumor activity. Safety and tolerability were as expected for a maytansinoid antibody-drug conjugate."
Clinical • Journal • P1 data • PK/PD data
1 to 1
Of
1
Go to page
1